Ramucirumab + Nivolumab
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer
Trial Timeline
Jan 1, 2017 → Aug 1, 2019
NCT ID
NCT02999295About Ramucirumab + Nivolumab
Ramucirumab + Nivolumab is a phase 1/2 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02999295. Target conditions include Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02999295 | Phase 1/2 | Completed |
Competing Products
20 competing products in Gastric Cancer